A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT06138132
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Multiple Sclerosis
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Secondary Progressive

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • KYV-101 anti-CD19 CAR-T cell therapy — BIOLOGICAL
    KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen — DRUG
    Standard lymphodepletion regimen

Study Details

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis

Key Dates

Start date
Apr 10, 2024
Status verified
Mar 2025
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: KYV-101 CAR-T cells with lymphodepletion conditioning
    Dosing with KYV-101 CAR T cells

Primary Outcome Measure

Frequency of dose limiting toxicities at each dose level [ Time Frame: Up to 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford Multiple Sclerosis CenterPalo AltoCalifornia94304
Emma Martinez, BA
[email protected]
650-387-5907
Jeffrey Dunn, MD (PRINCIPAL_INVESTIGATOR)
Everett Meyer, MD (SUB_INVESTIGATOR)
Robert Lowsky, MD (SUB_INVESTIGATOR)
Saurabh Dahiya, MD (SUB_INVESTIGATOR)
Jamie McDonald, MD, MS (SUB_INVESTIGATOR)
Garrett Timmons, MD (SUB_INVESTIGATOR)

Find similar trials in Palo Alto, CA

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
Stanford Multiple Sclerosis Center· Palo Alto, CA

Related Studies